| ||||||||||||||
|
|
|||||||||||||
Department of Anesthesiology, National Taiwan University Hospital, Taipei, Taiwan
Address correspondence and reprint requests to Li-Kuei Chen, MD, Department of Anesthesiology, National Taiwan University Hospital, No. 7, Chung-Shan South Rd., Taipei, Taiwan, 100.
| Abstract |
|---|
|
|
|---|
Implications: Ondansetron prophylaxis significantly decreases the incidence of pruritus, a common side effect of intrathecal morphine used to treat postcesarean delivery pain.
| Introduction |
|---|
|
|
|---|
Ondansetron, a selective serotonin type 3 receptor antagonist (4), is commonly used for nausea and vomiting in patients undergoing cancer chemotherapy. Several studies have shown that ondansetron is effective in treating pruritus of various causes, including intrathecal morphine-induced pruritus (511). In a prospective, randomized, double-blinded study, Borgeat and Stirnemann (12) demonstrated that ondansetron was effective in treating spinal or epidural morphine-induced pruritus. The incidence of intrathecal morphine-induced pruritus is especially high after cesarean delivery (13,14), but a study evaluating prophylaxis in patients undergoing cesarean delivery has never been reported. We therefore undertook a prospective, randomized, double-blinded clinical study to test the hypothesis that ondansetron is more effective in decreasing the incidence of pruritus associated with intrathecal injection of morphine in patients undergoing cesarean delivery than either placebo or diphenhydramine (commonly used to treat pruritus).
| Methods |
|---|
|
|
|---|
All patients received an intrathecal injection of 810 mg of bupivacaine (dosage adjusted according to body height) for spinal anesthesia and preservative-free morphine of 0.15 mg for postoperative pain control. The morphine was diluted with 0.9% saline to a concentration of 1 mg/mL. By using a 1-mL syringe, 0.15 mL of the diluted morphine was added to the bupivacaine solution, mixed well, and injected. The patients were randomly divided into three groups. Group 1 received placebo (normal saline) IV injection, Group 2 diphenhydramine 30 mg IV injection, and Group 3 ondansetron 0.1 mg/kg IV injection, immediately after the baby was delivered. All injections were IV infused for 10 min. The dose of ondansetron used was 0.1 mg/kg, and the average amount was 7.1 mg. This dose was chosen because it has previously been reported (4) and is similar to that which has been used in treating pruritus (12). The patients were evaluated by an anesthesia research fellow who was blinded to the treatment group. Evaluations were performed every 5 min in the first 2 h after the IV injection of the study medicine, every 15 min for another 2 h, then every 30 min in the following 24 h. Pruritus was evaluated for 28 h postoperatively. The following items were evaluated: symptoms and location of pruritus, postoperative pain, time to flatus passage, and previously reported adverse reactions of ondansetron including headache, cardiac arrhythmia, and extrapyramidal signs (4,15). The degree of pruritus was classified as 0 = no pruritus, 1 = mild pruritus (no treatment needed), and 2 = severe pruritus (treatment needed). Patients were asked about the presence of pruritus and whether treatment was wanted. If treatment was needed, propofol 10 mg was injected IV. Postoperative pain was evaluated by using a visual analog scale (from 0 = no pain to 100 = worst pain imaginable). Cardiac arrhythmia was evaluated with cardiac auscultation and patient report of palpitations. Twelve-lead electrocardiograms were performed for verification. The time to flatus passage was evaluated because ondansetron has been reported to be associated with constipation (4).
Data were presented as mean ± SD. The
2 test was used to test associations among dichotomous parameters, and Yates correction was used when necessary. Analysis of variance was used to compare numeric parameters among the three study groups.
| Results |
|---|
|
|
|---|
|
| Discussion |
|---|
|
|
|---|
The incidence of intrathecal morphine-induced pruritus in untreated patients in our study was similar to that reported in the literature (70%85%) (13,14). This pruritus is refractory to conventional antipruritic treatment, such as topical drug application and diphenhydramine or steroid injection (3). Several reports have shown promising results with ondansetron, a serotonin type 3 receptor antagonist (912). Borgeat and Stirnemann (12) reported that ondansetron was effective for the treatment of spinal or epidural morphine-induced pruritus in a randomized, double-blinded study of 100 patients. The incidence of prophylactic failure in our study was comparable to the treatment failure rates of previous reports (11,12).
The mechanisms of intrathecal morphine-induced pruritus remain unclear. The effectiveness of ondansetron to prevent and treat this pruritus indicates a role for serotonin type 3 receptors in its pathogenesis. It has been reported that serotonin type 3 receptors are abundant in the dorsal horn area of the spinal cord and in the spinal tract of the trigeminal nerve in the medulla (1619). The role of ondansetron in nociception has also been reported (20). Fan (21) reported that morphine can activate serotonin type 3 receptors by a mechanism independent of opioid receptors. Therefore, direct irritation of serotonin type 3 receptors in the dorsal horn of the spinal cord and in the medulla by intrathecal injection of morphine is a possible mechanism for the pruritus. This is also compatible with the clinical observation that pruritus occurred in an ascending pattern.
Because treatment for pruritus was considered absolutely necessary in only 20% (4 of 20) of patients in the placebo group, the routine prophylactic use of this drug may be associated with unnecessary drug administration in some patients who might not have developed pruritus or who would not have requested treatment. There are, however, no good predictors to indicate which patient will develop pruritus, and given the option, most patients would rather not experience this side effect. Although routine use of ondansetron would be associated with a somewhat higher cost of care, this might be balanced by greater patient satisfaction as a result of a decreased incidence of pruritus.
Although IV ondansetron significantly decreased the incidence of morphine-related pruritus, this complication still occurred in approximately 25% of patients. These patients might need other treatment, such as naloxone or propofol (12,22). Whether these patients might respond to more potent serotonin type 3 antagonists or a larger dose of ondansetron remains unclear. It is also possible that other mechanisms independent of serotonin receptors are involved in the pathogenesis of morphine-induced pruritus. A dose-response effect was not evaluated in our study and would be worthwhile to examine in a future study. Because ondansetron is lipophilic, it may be excreted in breast milk, although there are no reports defining the concentration of this drug in breast milk (23). Therefore, ondansetron is not currently recommended for routine use in breastfeeding mothers, and this may limit its use in patients undergoing cesarean delivery until further data are available.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. B. George, T. K. Allen, and A. S. Habib Serotonin Receptor Antagonists for the Prevention and Treatment of Pruritus, Nausea, and Vomiting in Women Undergoing Cesarean Delivery with Intrathecal Morphine: A Systematic Review and Meta-Analysis Anesth. Analg., July 1, 2009; 109(1): 174 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-P. Bonnet, E. Marret, J. Josserand, and F. J. Mercier Effect of prophylactic 5-HT3 receptor antagonists on pruritus induced by neuraxial opioids: a quantitative systematic review Br. J. Anaesth., September 1, 2008; 101(3): 311 - 319. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ganesh, A. Kim, P. Casale, and G. Cucchiaro Low-Dose Intrathecal Morphine for Postoperative Analgesia in Children Anesth. Analg., February 1, 2007; 104(2): 271 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Siddik-Sayyid, M. T. Aouad, S. K. Taha, M. S. Azar, M. A. Hakki, R. N. Kaddoum, V. G. Nasr, V. G. Yazbek, and A. S. Baraka Does Ondansetron or Granisetron Prevent Subarachnoid Morphine-Induced Pruritus After Cesarean Delivery? Anesth. Analg., February 1, 2007; 104(2): 421 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pirat, S. F. Tuncay, A. Torgay, S. Candan, and G. Arslan Ondansetron, Orally Disintegrating Tablets Versus Intravenous Injection for Prevention of Intrathecal Morphine-Induced Nausea, Vomiting, and Pruritus in Young Males Anesth. Analg., November 1, 2005; 101(5): 1330 - 1336. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Iatrou, C. K. Dragoumanis, T. D. Vogiatzaki, G. I. Vretzakis, C. E. Simopoulos, and V. K. Dimitriou Prophylactic Intravenous Ondansetron and Dolasetron in Intrathecal Morphine-Induced Pruritus: A Randomized, Double-Blinded, Placebo-Controlled Study Anesth. Analg., November 1, 2005; 101(5): 1516 - 1520. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Rathmell, T. R. Lair, and B. Nauman The Role of Intrathecal Drugs in the Treatment of Acute Pain Anesth. Analg., November 1, 2005; 101(5S_Suppl): S30 - 43. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-D. Roy, M. Girard, and P. Drolet Intrathecal Meperidine Decreases Shivering During Cesarean Delivery Under Spinal Anesthesia Anesth. Analg., January 1, 2004; 98(1): 230 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Szarvas, R. S. Chellapuri, D. C. Harmon, J. Owens, D. Murphy, and G. D. Shorten A Comparison of Dexamethasone, Ondansetron, and Dexamethasone plus Ondansetron as Prophylactic Antiemetic and Antipruritic Therapy in Patients Receiving Intrathecal Morphine for Major Orthopedic Surgery Anesth. Analg., July 1, 2003; 97(1): 259 - 263. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Charuluxananan, O. Kyokong, W. Somboonviboon, A. Narasethakamol, and P. Promlok Nalbuphine Versus Ondansetron for Prevention of Intrathecal Morphine-Induced Pruritus After Cesarean Delivery Anesth. Analg., June 1, 2003; 96(6): 1789 - 1793. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Twycross, M.W. Greaves, H. Handwerker, E.A. Jones, S.E. Libretto, J.C. Szepietowski, and Z. Zylicz Itch: scratching more than the surface QJM, January 1, 2003; 96(1): 7 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Gurkan and K. Toker Prophylactic Ondansetron Reduces the Incidence of Intrathecal Fentanyl-Induced Pruritus Anesth. Analg., December 1, 2002; 95(6): 1763 - 1766. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|